Quantcast

Latest Mylan Stories

2014-07-08 08:30:07

PITTSBURGH, July 8, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Telmisartan Tablets USP, 20 mg, 40 mg and 80 mg, the generic version of Boehringer Ingelheim's Micardis® Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of hypertension, to lower blood pressure. Telmisartan Tablets USP, 20 mg, 40 mg and 80...

2014-07-01 12:29:14

Mylan to Host Investor Day on Sept. 18, 2014 PITTSBURGH, July 1, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) announced today that it will host a conference call and live webcast on Thursday, Aug. 7, 2014, at 10:00 a.m. ET to review the company's financial results for the second quarter and first half ended June 30, 2014. Mylan will release its financial results on Aug. 7 before the market opens. http://photos.prnewswire.com/prnvar/20140423/77793 With respect to its guidance for...

2014-06-11 12:29:06

PITTSBURGH, June 11, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Risedronate Sodium Tablets USP, 150 mg, the generic version of Warner Chilcott's Actonel(®) Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women. Risedronate Sodium Tablets USP, 150 mg, had...

2014-06-09 08:28:26

PITTSBURGH, June 9, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin(®) Injection. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the initial treatment of advanced ovarian carcinoma in established combination...

2014-06-05 08:29:13

PITTSBURGH, June 5, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the Goldman Sachs 35(th) Annual Global HealthCare Conference on Tuesday, June 10, 2014, in Rancho Palos Verdes. The presentation is scheduled to begin at 8:40 a.m. PT. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at...

2014-06-03 12:31:25

LONDON, June 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:World OTC Pharmaceutical Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/country_reports_pharmaceutical/world_otc_pharmaceutical_market_2012_2022.html Report DetailsDiscover the highest potential revenues in over-the-counter medicineWhat does the future hold for OTC medicines? Visiongain's report shows you potential revenues to 2023, assessing data, trends, opportunities and...

2014-06-02 08:29:10

Mylan will launch all strengths at earliest market formation PITTSBURGH, June 2, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement and license agreement with Pfizer Inc. relating to Mylan's Abbreviated New Drug Application (ANDA) filed with the U.S. Food and Drug Administration (FDA) for Celecoxib Capsules, 50 mg, 100 mg, 200 mg and 400 mg. This product is the generic version of Celebrex(®), which is indicated for the relief of the...

2014-05-30 12:26:11

Expects to Imminently Receive Final Approval on 50 mg Strength; Has Received Tentative Approval on All Strengths PITTSBURGH, May 30, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today commented on the decision by the United States District Court for the Northern District of West Virginia denying Mylan's request for an injunction in its suit against the U.S. Food and Drug Administration (FDA), challenging the agency's decision regarding generic drug marketing exclusivity on Celecoxib...

2014-05-29 08:29:06

PITTSBURGH, May 29, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone(®) Tablets. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prophylaxis of Plasmodium falciparum malaria and the treatment of...

2014-05-28 12:30:09

PITTSBURGH, May 28, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL), one of the world's leading generic and specialty pharmaceutical companies, today announced that the company will present at the INVEST Pennsylvania Equity Conference on Thursday, May 29, 2014, in Pittsburgh. The presentation is scheduled to begin at 9:25 a.m. ET. Interested parties can access a live webcast of the presentation via the investor relations section of Mylan's Web site at http://mylan.com/investors. An...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related